Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

Comparing durability of leading hemophilia A gene therapies

BioMarin, Pfizer-Sangamo products keep patients in the mild disease category for at least two years, though Factor activity wanes

By Danielle Golovin, Staff Writer
January 13, 2022 1:43 AM UTC

New data provide an updated picture about the durability of hemophilia A gene therapies, showing that although Factor VIII activity wanes, the most advanced programs achieve activity levels that keep patients’ disease mild for at least two years. 

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced two-year results from the Phase III GENEr8-1 study of valoctocogene roxaparvovec to treat hemophilia A. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Biomarin Pharmaceutical Inc.

Pfizer Inc.

Sangamo Therapeutics Inc.

BCIQ Target Profiles

Factor VIII